2024 World Conference on Lung Cancer (WCLC) - Posters-P2.11A.01 Racial/ethnic Differences in Real-World Adverse Events and Survival Among Patients on Immunotherapy for Advanced NSCLC

P2.11A.01 Racial/ethnic Differences in Real-World Adverse Events and Survival Among Patients on Immunotherapy for Advanced NSCLC

Back to course

Pdf Summary

The document discusses a study examining racial and ethnic differences in survival and adverse events (AEs) among advanced non-small cell lung cancer (advNSCLC) patients undergoing immunotherapy. The main findings reveal that documented real-world adverse events (rwAEs) are linked to improved survival across all racial and ethnic groups. However, it notes that Latinx and Black patients had fewer documented rwAEs yet experienced better overall survival than White patients.<br /><br />Key findings include better overall survival for Latinx (HR: 0.90) and Black patients (HR: 0.89) compared to White patients. Asian patients also showed a survival advantage with an HR of 0.79. Despite the general correlation between AEs and extended survival, Latinx patients displayed less survival benefit from rwAEs for overall survival and no benefit for progression-free survival (PFS).<br /><br />The study employed the Flatiron Health EHR-derived database, analyzing a cohort of 33,943 patients across various ethnicities and collected from 280 cancer clinics. Utilizing machine learning for data extraction, racial/ethnic differences were assessed through multivariable Cox proportional hazards models, adjusting for clinical factors like age and therapy type.<br /><br />The document emphasizes the potential for clinician documentation bias, which may affect identifying AEs across different racial and ethnic groups. These biases could influence machine learning model outcomes, urging further research into the mechanisms behind racial and ethnic disparities in AEs and survival rates.<br /><br />In conclusion, this study highlights significant racial and ethnic disparities in documented rwAEs and survival outcomes in advNSCLC patients, calling for further investigation into the underlying causes of these differences to improve equity in cancer treatment outcomes.

Asset Subtitle

Gene Ho

Meta Tag

Speaker Gene Ho

Topic Metastatic NSCLC – Immunotherapy

Keywords

racial differences

ethnic disparities

non-small cell lung cancer

immunotherapy

adverse events

survival rates

Latinx patients

Black patients

machine learning

clinician documentation bias